Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats

Hisakazu Ohtani, Erika Hanada, Koujirou Yamamoto, Yasufumi Sawada, Tatsuji Iga

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In establishing a method of electrocardiographic (ECG) measurement for investigating drug-induced ECG changes, we examined the ECG effects and pharmacokinetics of terfenadine (TFN) and quinidine (QND) in rats. The time profiles of the plasma concentration and ECG parameters, such as the QT interval determined from limb lead II (QT-II) and the precordial chest lead (QT-V), heart rate and PR interval, were examined during constant intravenous infusion of TFN (5 or 15 mg/kg/h) or QND sulfate dihydrate (10 or 30 mg/kg/h). Both agents provided significant and concentration-dependent QT prolongation. The plasma concentrations (C10), where 10 ms of QT prolongation was observed, were 1.03 μM for TFN and 5.12 μM for QND, respectively. The calculated plasma unbound concentration of C10 (C(10·f)) was 10.3 nM for TFN and 3.82 μM for QND, which coincides with previously reported in vitro values of IC50 for potassium channels. The drug-induced QT prolongation was quantitatively reproduced in rats within the clinical concentration range. The usefulness of our methodology for the evaluation of arrhythmogenic hazards of the drugs was also demonstrated.

Original languageEnglish
Pages (from-to)1189-1196
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume19
Issue number9
Publication statusPublished - 1996 Sep
Externally publishedYes

Fingerprint

Terfenadine
Quinidine
Pharmacokinetics
Pharmaceutical Preparations
Potassium Channels
Intravenous Infusions
Inhibitory Concentration 50
Thorax
Extremities
Heart Rate
Lead

Keywords

  • electrocardiography
  • pharmacodynamics
  • QT interval
  • quinidine
  • terfenadine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. / Ohtani, Hisakazu; Hanada, Erika; Yamamoto, Koujirou; Sawada, Yasufumi; Iga, Tatsuji.

In: Biological and Pharmaceutical Bulletin, Vol. 19, No. 9, 09.1996, p. 1189-1196.

Research output: Contribution to journalArticle

Ohtani, Hisakazu ; Hanada, Erika ; Yamamoto, Koujirou ; Sawada, Yasufumi ; Iga, Tatsuji. / Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. In: Biological and Pharmaceutical Bulletin. 1996 ; Vol. 19, No. 9. pp. 1189-1196.
@article{51586a5e5cac47dcaae955fe0b82e888,
title = "Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats",
abstract = "In establishing a method of electrocardiographic (ECG) measurement for investigating drug-induced ECG changes, we examined the ECG effects and pharmacokinetics of terfenadine (TFN) and quinidine (QND) in rats. The time profiles of the plasma concentration and ECG parameters, such as the QT interval determined from limb lead II (QT-II) and the precordial chest lead (QT-V), heart rate and PR interval, were examined during constant intravenous infusion of TFN (5 or 15 mg/kg/h) or QND sulfate dihydrate (10 or 30 mg/kg/h). Both agents provided significant and concentration-dependent QT prolongation. The plasma concentrations (C10), where 10 ms of QT prolongation was observed, were 1.03 μM for TFN and 5.12 μM for QND, respectively. The calculated plasma unbound concentration of C10 (C(10·f)) was 10.3 nM for TFN and 3.82 μM for QND, which coincides with previously reported in vitro values of IC50 for potassium channels. The drug-induced QT prolongation was quantitatively reproduced in rats within the clinical concentration range. The usefulness of our methodology for the evaluation of arrhythmogenic hazards of the drugs was also demonstrated.",
keywords = "electrocardiography, pharmacodynamics, QT interval, quinidine, terfenadine",
author = "Hisakazu Ohtani and Erika Hanada and Koujirou Yamamoto and Yasufumi Sawada and Tatsuji Iga",
year = "1996",
month = "9",
language = "English",
volume = "19",
pages = "1189--1196",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats

AU - Ohtani, Hisakazu

AU - Hanada, Erika

AU - Yamamoto, Koujirou

AU - Sawada, Yasufumi

AU - Iga, Tatsuji

PY - 1996/9

Y1 - 1996/9

N2 - In establishing a method of electrocardiographic (ECG) measurement for investigating drug-induced ECG changes, we examined the ECG effects and pharmacokinetics of terfenadine (TFN) and quinidine (QND) in rats. The time profiles of the plasma concentration and ECG parameters, such as the QT interval determined from limb lead II (QT-II) and the precordial chest lead (QT-V), heart rate and PR interval, were examined during constant intravenous infusion of TFN (5 or 15 mg/kg/h) or QND sulfate dihydrate (10 or 30 mg/kg/h). Both agents provided significant and concentration-dependent QT prolongation. The plasma concentrations (C10), where 10 ms of QT prolongation was observed, were 1.03 μM for TFN and 5.12 μM for QND, respectively. The calculated plasma unbound concentration of C10 (C(10·f)) was 10.3 nM for TFN and 3.82 μM for QND, which coincides with previously reported in vitro values of IC50 for potassium channels. The drug-induced QT prolongation was quantitatively reproduced in rats within the clinical concentration range. The usefulness of our methodology for the evaluation of arrhythmogenic hazards of the drugs was also demonstrated.

AB - In establishing a method of electrocardiographic (ECG) measurement for investigating drug-induced ECG changes, we examined the ECG effects and pharmacokinetics of terfenadine (TFN) and quinidine (QND) in rats. The time profiles of the plasma concentration and ECG parameters, such as the QT interval determined from limb lead II (QT-II) and the precordial chest lead (QT-V), heart rate and PR interval, were examined during constant intravenous infusion of TFN (5 or 15 mg/kg/h) or QND sulfate dihydrate (10 or 30 mg/kg/h). Both agents provided significant and concentration-dependent QT prolongation. The plasma concentrations (C10), where 10 ms of QT prolongation was observed, were 1.03 μM for TFN and 5.12 μM for QND, respectively. The calculated plasma unbound concentration of C10 (C(10·f)) was 10.3 nM for TFN and 3.82 μM for QND, which coincides with previously reported in vitro values of IC50 for potassium channels. The drug-induced QT prolongation was quantitatively reproduced in rats within the clinical concentration range. The usefulness of our methodology for the evaluation of arrhythmogenic hazards of the drugs was also demonstrated.

KW - electrocardiography

KW - pharmacodynamics

KW - QT interval

KW - quinidine

KW - terfenadine

UR - http://www.scopus.com/inward/record.url?scp=0029842313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029842313&partnerID=8YFLogxK

M3 - Article

C2 - 8889039

AN - SCOPUS:0029842313

VL - 19

SP - 1189

EP - 1196

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 9

ER -